×
About 4,123 results

ALLMedicine™ Antiphospholipid Syndrome Center

Research & Reviews  1,534 results

Cost-effectiveness analysis of treatments for the first episode of catastrophic antipho...
https://doi.org/10.1177/09612033211070973
Lupus Quintana-López G, Rodríguez-Pintó I et. al.

Jan 18th, 2022 - Treatments for catastrophic antiphospholipid syndrome (CAPS) rose from recommendations and consensus of international experts based on case series or case reports. We aimed to evaluate the treatment scheme with the best cost-effectiveness ratio as...

Interaction between Antiphospholipid Antibodies and Protein C Anticoagulant Pathway: A ...
https://doi.org/10.1055/s-0041-1742083
Seminars in Thrombosis and Hemostasis; Pengo V

Jan 13th, 2022 - Thrombotic antiphospholipid syndrome (APS) is a condition in which thrombosis in venous, arterial, and/or small vessels is ascribed to the presence of antiphospholipid antibodies (aPL). Among the various proposed pathogenic theories to explain thr...

Safety and Immunogenicity of Sars-cov-2 Vaccine in Patients With Rheumatic Diseases
https://clinicaltrials.gov/ct2/show/NCT05191368

Jan 13th, 2022 - Rheumatic diseases (RDS) are a large class of systemic diseases caused by genetic background, environment and physics, infection, metabolism, endocrine, immune response and other reasons, mainly involving joints and surrounding tissues. The diseas...

Rare yet catastrophic presentation of undiagnosed antiphospholipid syndrome.
https://doi.org/10.1136/bcr-2021-245838
BMJ Case Reports; Kwak S, Green M

Jan 12th, 2022 - A previously well 31-year-old woman initially presented to the emergency department with pneumonia, however, was found to be hypertensive and have new-onset cardiomegaly. She was admitted for intravenous antibiotics and concurrently a series of in...

see more →

Guidelines  4 results

First Latin American clinical practice guidelines for the treatment of systemic lupus e...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225798
Annals of the Rheumatic Diseases; Pons-Estel BA, Bonfa E et. al.

Jul 27th, 2018 - Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therap...

European evidence-based recommendations for diagnosis and treatment of paediatric antip...
https://doi.org/10.1136/annrheumdis-2016-211001
Annals of the Rheumatic Diseases; Groot N, de Graeff N et. al.

May 6th, 2017 - Antiphospholipid syndrome (APS) is rare in children, and evidence-based guidelines are sparse. Consequently, management is mostly based on observational studies and physician's experience, and treatment regimens differ widely. The Single Hub and A...

Practice Bulletin No. 132: Antiphospholipid syndrome.
https://doi.org/10.1097/01.AOG.0000423816.39542.0f
Obstetrics and Gynecology;

Nov 22nd, 2012 - Antiphospholipid syndrome (APS) is an autoimmune disorder defined by the presence of characteristic clinical features and specified levels of circulating antiphospholipid antibodies (Box 1 and Box 2). Diagnosis requires that at least one clinical ...

ACOG Practice Bulletin No. 118: antiphospholipid syndrome.
https://doi.org/10.1097/AOG.0b013e31820a61f9
Obstetrics and Gynecology;

Dec 22nd, 2010 - ACOG Practice Bulletin No. 118: antiphospholipid syndrome.|2010||

see more →

Clinicaltrials.gov  20 results

Safety and Immunogenicity of Sars-cov-2 Vaccine in Patients With Rheumatic Diseases
https://clinicaltrials.gov/ct2/show/NCT05191368

Jan 13th, 2022 - Rheumatic diseases (RDS) are a large class of systemic diseases caused by genetic background, environment and physics, infection, metabolism, endocrine, immune response and other reasons, mainly involving joints and surrounding tissues. The diseas...

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
https://clinicaltrials.gov/ct2/show/NCT02295475

Aug 26th, 2021 - This study is a prospective, open-label, blinded event, pilot study that will randomize patients with a history of venous thrombosis and antiphospholipid syndrome (APS) already receiving anticoagulation to either warfarin or apixaban. The study wi...

Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
https://clinicaltrials.gov/ct2/show/NCT04855513

Aug 25th, 2021 - Preeclampsia (PET) is one of the leading causes of maternal morbidity and mortality . Its pathophysiology is poorly understood. Consequently, there are no efficient preventive and treatment modality. PET is associated with significant perinatal mo...

Hydroxychloroquine in Prevention of Preeclampsia
https://clinicaltrials.gov/ct2/show/NCT04755322

Jul 23rd, 2021 - Pre-eclampsia complicates up to 8% of pregnancies and is a major contributor to maternal mortality and morbidity The only effective treatment is delivery, which leads to significant neonatal morbidity and mortality if carried out preterm, especial...

Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02600260

Apr 28th, 2021 - Thromboembolic events are among the leading causes of maternal morbidity and mortality in pregnancy / postpartum period. They are the leading cause of maternal death in developed countries. Risk factors for venous thromboembolism (VTE) during preg...

see more →

News  88 results

Low Preconception Complement Levels Linked to Adverse Pregnancy Outcomes in Antiphospholipid Syndrome
https://www.medscape.com/viewarticle/960632

Oct 11th, 2021 - Low serum levels of two complement proteins are linked to worse pregnancy outcomes in women with antiphospholipid syndrome (APS), the results of a multicenter study appear to confirm. The study evaluated preconception complement levels in 260 preg...

FDA Approves First Oral Anticoagulant for Children
https://www.medscape.com/viewarticle/953535

Jun 22nd, 2021 - The US Food and Drug Administration (FDA) has approved dabigatran etexilate (Pradaxa) oral pellets for the treatment of venous thromboembolism (VTE) in children aged 3 months to less than 12 years. The drug is to be administered immediately after ...

New Side Effect From mRNA COVID Vaccines?
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/92106

Apr 15th, 2021 - Herpes zoster reactivation -- a.k.a. shingles -- following COVID-19 vaccination in six patients with comorbid autoimmune/inflammatory diseases may be a new adverse event associated with the Pfizer/BioNTech mRNA vaccine, suggested a new report. At ...

Managing Diffuse Peripheral Ischemia in Antiphospholipid Syndrome: Anticoagulation, Immunosuppression, or Vasodilation?
https://www.medscape.com/viewarticle/948988

Apr 14th, 2021 - This article originally appeared on Hospital for Special Surgery's website. Case Report A 39-year-old man with a history of well-controlled type 1 diabetes (T1D) since childhood and migraine presented with 1 week of pain and cyanosis of the finger...

Managing Diffuse Peripheral Ischemia in Antiphospholipid Syndrome: Anticoagulation, Immunosuppression, or Vasodilation?
https://www.medscape.com/viewarticle/948988?src=sapfe

Apr 14th, 2021 - This article originally appeared on Hospital for Special Surgery's website. Case Report A 39-year-old man with a history of well-controlled type 1 diabetes (T1D) since childhood and migraine presented with 1 week of pain and cyanosis of the finger...

see more →

Patient Education  3 results see all →